Empagliflozin significantly increased peak oxygen consumption by 23.9% and reduced the VE/VCO2 slope by 15.8% compared to baseline in patients with type 2 diabetes.
Cohort (n=20)
Open-label
No
Does empagliflozin improve cardiorespiratory fitness in patients with type 2 diabetes?
Empagliflozin significantly improved markers of cardiorespiratory fitness, including peak VO2 and VE/VCO2 slope, in patients with type 2 diabetes, providing potential mechanistic insights into its cardiovascular benefits.
Absolute Event Rate: 20.5% vs 19.68%
p-value: p=0.01
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to prevent heart failure and reduce cardiovascular death in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Whether or not SGLT2 inhibitors improve indices of cardiorespiratory fitness (CRF), an independent predictor of mortality in patients with CVD, remains unknown. We evaluated the effects of empagliflozin on indices of CRF in patients with T2DM. Twenty patients with T2DM received either empagliflozin 10 mg or usual care. Baseline and 3- to 6-month post-treatment measurements of CRF were evaluated using cardiopulmonary exercise testing on a cycle ergometer. Treatment with empagliflozin led to an increased peak oxygen consumption (VO 2 ), reduction in VE/VCO 2 slope, and improvement in heart rate recovery. Our results suggest that SGLT2 inhibitors may improve markers of CRF in patients with T2DM. This may help provide important clues into the mechanism of benefit of SGLT2 inhibitors in clinical trials and provide a translational framework for the ongoing large studies of SGLT2 inhibitors in the treatment of heart failure.
Kumar et al. (Fri,) conducted a cohort in Type 2 diabetes and high cardiovascular risk (n=20). Empagliflozin vs. Usual care was evaluated on Peak oxygen consumption (VO2) (p=0.01). Empagliflozin significantly increased peak oxygen consumption by 23.9% and reduced the VE/VCO2 slope by 15.8% compared to baseline in patients with type 2 diabetes.